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Question of the study: We studied whether prophylactic use of noninvasive pressure
support ventilation (NIPSV) administered pre- and postoperatively may reduce the
postoperative pulmonary function impairment.
Patients and methods: Prospective randomized clinical trial. Thirty-nine patients with a
preoperative FEV1o70% of the predicted value scheduled for elective lobectomy related
to lung cancer were enrolled. Seven patients were excluded after enrollment. Patients
were required to follow standard treatment without (control group, n ¼ 18) or with NIPSV
(study group, n ¼ 14) during 7 days at home before surgery, and during 3 days
postoperatively. Primary outcome variable was the changes on arterial blood gases on
room air.
Results: Two hours after surgery, PaO2, FVC and FEV1 values were significantly better in
the NIPSV group. On day 1, 2 and 3, PaO2 was significantly improved in the NIPSV group.
Also on day 1, FVC and FEV1 improved significantly in the NIPSV group. The hospital stay
was significantly longer in the control group than in the study group (p ¼ 0.04). The
incidence of major atelectasis was 14.2% in the NIPSV group and 38.9% in the no-NIPSV
group (p ¼ 0.15).Elsevier Ltd. All rights reserved.
itive airway pressure; EPAP, expiratory positive airway pressure; FEV1, forced expiratory volume in 1 s;
ive care unit; IPAP, inspiratory positive airway pressure; PaCO2, arterial carbon dioxide tension; PaO2,
ressure; SD, standard deviation; NIPSV, noninvasive pressure support ventilation
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Preventive use of noninvasive ventilation 1573Answer to the question: Prophylactic use of NIPSV in a pre- and postoperative manner
significantly reduces pulmonary dysfunction after lung resection. As a result, recovery of
preoperative respiratory function is accelerated.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Lung resectional surgery is often complicated by significant
pulmonary dysfunction that persists for a few days after
surgery.1–3 Alteration of ventilatory function is multifactor-
ial; reflex inhibition of the phrenic nerve, anesthesia, chest
pain, closure of distal airways and the loss of functioning
parenchyma, all contribute to these changes.2,3 This
pulmonary function impairment may lead to postoperative
pulmonary complications such as sputum retention, atelec-
tasis, pneumonia and respiratory failure with prolonged
mechanical ventilation.4 Furthermore, it has been suggested
that an increased risk of postoperative pulmonary dysfunc-
tion is associated with a preoperative forced expiratory
volume in 1 s (FEV1) or forced vital capacity (FVC) of less
than 70% of the predicted value.5 Continuous positive airway
pressure (CPAP) administered by full face or nasal mask in
the postoperative phase can restore functional residual
capacity to preoperative values,6 improve oxygenation,7
and spare inspiratory muscles.8 Although CPAP seems to be
more effective than routine chest physiotherapy,9 its
benefits are unfortunately not sustained, and functional
residual capacity deteriorates a few minutes after interrup-
tion of CPAP.6 Noninvasive pressure support ventilation
(NIPSV) is a recognized treatment for acute hypercapnic
and hypoxemic acute respiratory failure.10,11 In comparison
to CPAP, relatively high inspiratory pressure is used with
NIPSV. As a result, NIPSV may improve the distribution of
ventilation by recruiting zones of alveolar collapse.12 Also,
NIPSV minimizes the work of breathing.8 Although the
postoperative preventive use of NIPSV may improve oxyge-
nation in nonhypercapnic patients,13–15 prophylactic NIPSV
therapy used pre- and postoperatively in patients with
severe preoperative pulmonary function impairment sub-
mitted to elective lung resection has never been studied. In
this randomized-controlled study, we tested if the perio-
perative prophylactic use of NIPSV promoted better recov-
ery of arterial blood gases and pulmonary function after lung
resectional surgery.
Methods
Patients
This investigation was approved by our institution’s Ethics
Committee. Written consent was obtained from all partici-
pants after they were fully informed of the nature,
characteristics, aims, and potential risks of the study.
All patients with preoperative FEV1o70% of the predicted
value and scheduled for elective lobectomy related to lung
cancer between January 2001 and January 2004 were
initially considered as potential candidates. Patients were
excluded if one or more of these conditions occured: (1)
incisions other than posterolateral thoracotomy, (2) minor
pulmonary resection such as open lung biopsies, (3)exploratory thoracotomy (no parenchymal resection), (4)
pneumonectomy, (5) previous treatment with NIPSV or CPAP,
(6) postoperative hemodynamic instability (ventricular
dysrythmia and myocardial ischemia or infarction) or acute
respiratory failure that required endotracheal mechanical
ventilation, (7) pregnancy, (8) mental retardation or other
severe cognitive disorders, and inability to provide informed
consent. Standard anesthetic procedures were used in all
patients. These techniques have been described elsewhere
in the literature.16 Surgical techniques were those of
standard pulmonary resection. After surgery, the patients
were placed in the surgical intensive care unit (ICU) for at
least 4 days. During this period of time, all patients received
a thoracic epidural analgesia with continuous infusion of
ropivacaine 0.2% combined with sufentanil (1 or 0.5 mg/ml if
age was over 70 years). An infusion started 1 h before the
end of surgery at a rate of 6ml/h, and was adjusted
thereafter according to the visual analog scale.
Study design
This study was designed as a randomized, controlled, and
parallel trial. Seven days prior surgery, enrolled patients
visited our outpatient pulmonary clinic. Vital signs were
measured and patients were randomly assigned to standard
treatment without (Control Group) or with NIPSV (Study
Group). Randomization was achieved using sealed envelopes
with the order of distribution determined by computer
generated randomized numbers. Patients in both groups
were required to follow the treatment during 7 days at home
before surgery, and during 3 days postoperatively.
Standard treatment
All patients of both groups received all therapeutic
measures necessary to provide optimal care for the patient
and systematically: aerosolized terbutaline (10mg/24 h) and
ipratropium bromure (1mg/24 h), oral ambroxol (60mg/
24 h) and chest physiotherapy. Chest physiotherapy was
performed with the same regimen during the preoperative
period at home and during the postoperative phase. At
home, a private physiotherapist contacted by the principal
investigator had in charge the patient. Chest physiotherapy
was performed twice a day at 10 am and 2pm. Patients were
instructed to take four to five maximal inspirations and then
to cough heartily every 3min during 15min. Furthermore,
patients carried out deep breathing exercises taking 20
maximal inspirations and 20 maximal expirations with the
aid of a deep breathing exerciser (Triflo, Chesebrough-
Pond’s Inc.).
NIPSV
Ventilation was provided via an industrial facial mask
(Mirages, Resmed, Sidney, Australia). NIPSV was provided
with a pressure-preset ventilator (VPAP ST3s, Resmed,
Sidney, Australia) in the spontaneous mode. This device
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positive airway pressure (IPAP) and an expiratory positive
airway pressure (EPAP). The IPAP level was maintained for at
least 0.1 s and could not exceed 2 s. The ventilator cycled to
EPAP when the patient inspiratory flow decreased below a
threshold level. If an expiratory effort was detected or if
inspiratory period was held for more than 2 s, the device
automatically swiched from IPAP to EPAP. NIPSV was initiated
in our outpatient pulmonary clinic 7 days prior surgery. IPAP
was initially set at 8 cmH2O and then was increased until the
maximal level tolerated by the patient was reached. EPAP
was set at 2–4 cmH2O. Patients were acclimatized to NIPSV
during a 1 h period under the supervision of one of the
investigators. During this training trial, pulse oximetry was
recorded and arterial blood gases were obtained. Preopera-
tively, patients were required to perform NIPSV at least five
1-h period per day. Postoperatively, the same NIPSV regimen
was required with the exception of the first 2 h following
surgery during which the patients were not wearing NIPSV.
Throughout the study, the inspired concentration of oxygen
with NIPSV was 0.21. Patients’adherence to NIPSV at home
was determined by the ventilator timer and checked by the
same manner in the ICU.
Measurements
Resting daytime blood gases (Ciba-Corning 288 blood gas
analyzer, Medfield, MA, USA) were obtained from the radial
artery with the patient breathing room air pre- and
postoperatively in both groups. In the study group and on
room air, arterial blood gases were systematically performed
before NIPSV sessions pre- and postoperatively.
Preoperatively, static lung volumes were determined by a
constant-volume whole body plethysmograph (Jaeger Mas-
terscreen Body, Wuerzburg, Germany) and, FEV1 and FVC
were measured with a pneumotachograph (Jaeger Mastersc-
reen Body, Wuerzburg, Germany). Postoperatively, FVC and
FEV1 were also recorded using a spirometer (Hyco & Aulas,
Buckingham, England). Pre- and postoperatively, pulmonary
function was measured in the sitting position by the same
technician blind as to patient randomization. Preopera-
tively, arterial blood gases and pulmonary function were
systematically assessed as patients were randomized and
after 7 days of treatment at home. Postoperatively the same
parameters were measured on operative day (2 h after
surgery), and at 10 am on day 1, day 2, and day 3. Pain and
dyspnea scores, heart rate, respiratory rate, arterial blood
pressure, opioid consumption were recorded by nurses on
the surgical ICU every 4 h postoperatively. In both groups,
chest X-rays obtained 2 h after surgery and, at 9 am on the
first, second and third postoperative days were assessed by 2
radiologists (BP and AC) who were blinded to the patient’s
randomization. Lobar or supralobar atelectasis requiring a
fiberoptic bronchoscopy have been recorded. Duration of in-
hospital stay was also recorded.
Statistical analysis
The primary outcome variable was the changes in arterial
blood gases on room air. Secondary outcomes were changes
in lung function, the rate of postoperative lobar orsupralobar atelectasis and duration of in-hospital stay.
Results are reported as mean7SD. For the between-groups
comparison and for comparison at different times, a
repeated analysis of variance (ANOVA) was used. If a
significant difference was noted, pairwise comparisons were
performed by the Student–Newman–Keuls test to account
for multiple comparisons. p-Values at 0.05 or less were
considered to be statistically significant.Results
Between January 2001 and January 2004, 300 patients have
been scheduled for elective lobectomy related to lung
cancer. Among them, 39 patients were enrolled in the study.
Seven patients were excluded after enrollment. One patient
in the control group was excluded for immediate post-
operative acute respiratory failure related to total pneu-
mothorax, which has required invasive mechanical
ventilation. Six patients in the study group were excluded
(3 for pneumonectomy and 3 for minor pulmonary resec-
tion). The two groups were similar with regard to age, body
mass index, preoperative pulmonary function and arterial
blood gases, duration of surgery, duration of lung deflation,
and opioid consumption during surgery and during the first
72 h postoperatively (Table 1). Although, 7 of 14 patients in
the study group were current smokers just before surgery as
compared to 9 of 18 in the control group, the patients in the
study group smoked significantly much more than the
control group, respectively, 80711 (mean7SD) packets
year versus 5975 packets year (p ¼ 0.04).
Patients’ compliance to NIPSV was 471 h/day preopera-
tively at home and 571 h/day postoperatively. The average
inspiratory pressure support level was 12.671.2 cmH2O and
the average expiratory pressure level was 2.970.7 cmH2O.
Regarding to the pre- and postoperative periods and as
compared to the control group, the use of NIPSV significantly
improved the overall evolution of the arterial blood gas
values measured on room air (pH (p ¼ 0.0003), arterial
carbon dioxide tension (PaCO2) (p ¼ 0.04), arterial oxygen
tension (PaO2) (p ¼ 0.0006)), FVC (p ¼ 0.03) and FEV1
(p ¼ 0.02). Before surgery and as compared to the control
group, arterial blood gases measured on room air improved
significantly after 7 days of treatment with NIPSV. Further-
more, a trend to improve FVC and FEV1 was observed with
NIPSV preoperatively in the study group. Two hours after
surgery and before NIPSV, as compared to the preoperative
values, arterial blood gases on room air, FVC and FEV1
significantly worsened in both groups. However, the values
of PaO2, FVC and FEV1 remained at a significant higher level
in the study group. Subsequently, arterial blood gas values
and pulmonary function parameters progressively returned
to preoperative values. The effect of NIPSV on arterial blood
gases, FVC and FEV1 are presented in Figs. 1 and 2. PaO2
values were significantly greater in the study group than the
control group at the four postoperative time points. FVC and
FEV1 values were also significantly increased in the study
group, respectively, on the first and third postoperative days
and on the postoperative day 1.
The development of postoperative chest X-ray lobar or
supralobar atelectasis has been assessed with an excellent
concordancy between the two radiologists (K ¼ 0.832).
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Table 1 Preoperative characteristics of patients.
Control group (n ¼ 18) Mean7SD Study group (n ¼ 14) Mean7SD p-Value
Age (years) 6373 6472 0.6
Body mass index (kg/m2) 2471 2571 0.6
Arterial blood gases (room air)
pH 7.4270.01 7.4270.01 0.8
PaO2 (mmHg) 74.171.6 75.071.7 0.7
PaCO2 (mmHg) 39.170.9 39.570.9 0.8
Pulmonary function testing
FVC (% pred) 84.9718.8 88.4715.4 0.5
FEV1 (% pred) 53.7710.0 54.979.2 0.7
PEFR (% pred) 53.6715.0 55.5712.2 0.7
Duration of surgery (min) 149715 158715 0.6
Duration of one lung deflation (min) 121711 110710 0.5
Opioid consumption (mg)
During surgery 115723 9079 0.4
During the first 72 h postoperatively 32.975.8 32.275.9 0.5
PaCO2 ¼ arterial carbon dioxide tension; PaO2 ¼ arterial oxygen tension; FVC ¼ forced vital capacity; FEV1 ¼ forced expiratory
volume in 1 s; PEFR ¼ peak expiratory flow rate; % pred ¼ percentage of the predicted value.
p-Values refer to between-group comparisons.
Preventive use of noninvasive ventilation 1575In the control group, five of the 18 patients (27.7%) had an
atelectatic consolidation on the first postoperative day, this
figure increasing to 7 of 18 on the third postoperative day
(38.9%). In the study group, two of 14 patients (14.2%) got
an atelectasis on the second postoperative day. The
difference between the two groups was not significant
(p ¼ 0.15).
NIPSV was mostly well tolerated. No patient died and no
complications, such as nasal abrasion, aspiration, gastric
distension or hemodynamic derangement were observed.
The incidence of supraventricular dysrythmia and the
duration of thoracic drainage were not different between
the two groups.
The hospital stay was significantly longer in the control
group (1973 days) than in the study group (1271 days,
p ¼ 0.04).Discussion
This study demonstrates that preventive NIPSV therapy used
pre- and postoperatively in patients with a preoperative
FEV1o70% of the predicted value submitted to elective lung
resection improves the overall perioperative evolution of
arterial blood gas values and pulmonary function para-
meters. We show that the preoperative use of NIPSV may
reduce the immediate postoperative hypoxemia and pul-
monary function impairment developed after such a surgery.
Our results also demonstrate that the prophylactic use of
NIPSV during the first 72 h postoperatively leads to quicker
recovery of preoperative arterial blood gas values and
spirometric volumes. In our study, although the incidence of
postoperative atelectatic consolidation is not significantly
different, the prophylactic use of NIPSV decreases the
length of in-hospital stay.
Although, the postoperative preventive use of NIPSV has
already been reported in patients undergoing lung resec-tional surgery,13 in obese patients undergoing gastroplasty14
or after coronary bypass grafting,15 its prophylactic use in
patients with a severe preoperative airflow obstruction has
never been previously tested. Indeed, the patients enrolled
in the studies from Aguilo et al.13 and Matte et al.15 had,
respectively, mild preoperative airflow obstruction or
normal preoperative spirometric values. In the work from
Joris et al.,14 preoperative pulmonary function was char-
acterized by a restrictive syndrome. In our study, the
preoperative values of FVC and FEV1 were, respectively,
lower than 90% and 55% of the predicted value in both
groups. Patients in the study group had smoked significantly
much more in the past. As a result, our study group had a
stronger risk for postoperative pulmonary complications as
compared to the control group.4 Several hypotheses may be
proposed to explain our positive results. Firstly and as
compared to CPAP, the IPAP level used with NIPSV promotes
lung inflation leading to alveolar recruitment. Thus, re-
expansion of micro-atelectatic areas by positive pressure
ventilation might explain the improvement of blood gases on
room air and pulmonary function parameters.17,18 Secondly,
the use of a facial mask may have reduced mouth leaks
induced by a sleepy state related to the residual sedative
effect of the anesthetic agents, as well as of the opioid
administered for postoperative analgesia. Furthermore, as it
has been demonstrated, oronasal mask is better tolerated in
the acute setting.19 Thirdly, the ‘‘pressure boost’’ (IPAP-
EPAP) that we used might have played a role. In our study,
the average inspiratory pressure support level was
12.671.2 cmH2O and the average expiratory pressure level
was 2.970.7 cmH2O. Then, the actual level of inspiratory
support was 9.7 cmH2O. In a prospective randomized
controlled study, Joris et al.14 have investigated the effect
of NIPSV on postoperative pulmonary function in obese
patients after gastroplasty. In this study, the authors
observed a ‘‘dose-dependent effect’’ of inspiratory support
on the postoperative pulmonary restrictive syndrome,
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Figure 1 Effect of NIPSV on PaO2, PaCO2 and pH (on room air). Patients had standard treatment (control group) or standard
treatment plus NIPSV (NIPSV group) during 7 days at home before surgery and 3 days postoperatively. Arterial blood gases were
performed preoperatively (before (Pr1) and after (Pr2) treatment) and postoperatively (2 h after surgery (D0) and on day 1, day 2 and
day 3). Note that arterial blood gases were performed before NIPSV sessions in the NIPSV group. Data are mean7SD. *po0.05
(control versus NIPSV groups); #po0.05 (Pr2 versus D0).
C. Perrin et al.1576comparing NIPSV 8/4 with inspiratory and EPAP set at 8 and
4 cmH2O, respectively, versus NIPSV 12/4 set at 12 and
4 cmH2O. As a result, patients with severe preoperative
pulmonary function may require a higher-pressure boost to
yield a reduction of the postoperative pulmonary function
impairment. In our study, lung inflation produced by a
9.7 cmH2O pressure boost might have been sufficient and not
high enough to be poorly tolerated. In particular, no
complications such as gastric distension, bronchus joining
troubles or hemodynamic derangement has been observed.Fourthly, NIPSV used preoperatively improved significantly
the arterial blood gas values and a trend to improve the
spirometric parameters was observed. As a result, the
preoperative use of NIPSV may have played a role in
decreasing immediate postoperative hypoxemia and pul-
monary function impairment. Furthermore, we argue that
the preoperative patients’ training to NIPSV may have been
of value in the overall postoperative improvement of these
parameters. In a study designed to compare the outcome of
episodes of acute exacerbation of chronic obstructive
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Figure 2 Effect of NIPSV on FVC and FEV1. For the method, see legend of Fig. 1. Data are mean7SD. *po0.05 (control versus NIPSV
groups); #po0.05 (Pr2 versus D0).
Preventive use of noninvasive ventilation 1577pulmonary disease treated with NIPSV in patients with home
NIPSV and in patients without home ventilatory support,
Hilbert et al.20 have demonstrated that previous experience
with NIPSV could benefit patients in the management of
acute respiratory failure.
Because of the too limited number of included patients,
our study was not designed to demonstrate any potential
benefit of prophylactic use of NIPSV on the incidence of
postoperative pulmonary complications, however, we report
a trend to reduce the incidence of lobar or supralobar
atelectasis.
In our study, the hospital stay was significantly shortened
by NIPSV. The quicker recovery of preoperative arterial
blood gases and spirometric volumes may be an explanation.
However, length of stay depends on many factors besides
just the medical condition. Indeed, we cannot exclude a
bias related to the facility for our patients to get earlier the
institution for rehabilitation. Also, because patients and
caregivers cannot be blinded to treatment group, further
potential bias is impossible to eliminate.
In conclusion, prophylactic NIPSV therapy used pre-and
postoperatively allows a significant reduction in the
magnitude of the postoperative arterial blood gases and
pulmonary function impairment in patients with a
preoperative FEV1o70% of the predicted value undergoing
lung resectional surgery. As a result, recovery of preopera-
tive respiratory function is accelerated. However, further
studies are required to assess the precise impact of theprophylactic use of NIPSV on postoperative pulmonary
complications.Acknowledgment
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